US EditionFDA Approves First Drug to Delay the Onset of Congestive Heart Failure in Dogs
- The U.S. Food and Drug Administration has approved VETMEDIN to delay the onset of congestive heart failure in dogs with Stage B2 myxomatous mitral valve disease .
- VETMEDIN is the only drug approved to treat preclinical heart disease in dogs, extending their symptom-free life.
- According to the EPIC study, VETMEDIN delayed the onset of CHF by 15.6 months in dogs with Stage B2 preclinical MMVD compared to the control group.
- This approval marks the first full FDA approval for an animal drug indication that was initially conditionally approved in 2022.
47 Articles
47 Articles
US FDA approves first drug to delay heart failure in dogs
Jan 19 (Reuters) - Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable tablet, as the first drug to delay congestive heart failure in dogs with a type of early-stage heart disease....
Bennington Banner
FDA approves first drug to delay the onset of congestive heart failure in dogs
Heart disease affects approximately 10 percent of dogs in their lifetime1VETMEDIN® (pimobendan) from Boehringer Ingelheim is the only medication approved to treat preclinical mitral valve disease in dogsAn expansion of a conditional approval, the FDA authorization broadens the use of…
The veterinary medicine took a historic step after the decision of the U.S. Food and Drug Administration (FDA).The regulatory agency definitively approved a chewable tablet developed by Boehringer Ingelheim, making it the first treatment capable of delaying congestive heart failure in dogs with a heart condition detected in early stages.You CAN SEE: FDA Alert: Remove POPULAR snack in the U.S. for possible contamination The drug is intended for a…
FDA Approves VETMEDIN, First Drug to Delay Onset of Congestive Heart Failure in Dogs
Boehringer Ingelheim, a global leader in animal health, recently announced that the U.S. Food and Drug Administration (FDA) has approved VETMEDIN (pimobendan) Chewable Tablets and VETMEDIN Solution (pimobendan oral solution), for the delay of onset of congestive heart failure (CHF) in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD). VETMEDIN is the only medication approved to treat preclinical heart disease in dogs and exte…
The pharmaceutical company Boehringer Ingelheim reported on Monday, January 19, that the U.S. Food and Drug Administration (FDA) approved its chewable tablet as the first drug to delay congestive heart failure in dogs with an early stage type of heart disease. The approval refers to dogs with heart disease, known as mixomatous mitral valve disease, which show signs of heart enlargement but still have no symptoms. According to the FDA, Vetmedin c…
US FDA approves first drug to delay heart failure in dogs - Regional Media News
Jan 19 (Reuters) - Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable tablet, as the first drug to delay congestive heart failure in dogs with a type of early-stage heart disease. The approval covers dogs with a heart condition, known as myxomatous mitral valve disease, who show signs of heart enlargement but do not yet have symptoms. The FDA said Vetmedin can now be used to…
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
